Greg Profile
Greg

@GregNowakowski

Followers
727
Following
295
Media
15
Statuses
72

oncology hematology lymphoma ASCO ASH

Minnesota, USA
Joined April 2013
Don't wanna be here? Send us removal request.
@vit_prochazka
Vít Procházka 🇨🇿🇪🇺🇺🇦
5 months
Right in time! Nice paper of 🇮🇹🇨🇿🇨🇭🇺🇸centers out! Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG) ⁦@StefanoLuminari⁩ ⁦@GregNowakowski⁩ ⁦@MarekTrnenyDr
0
2
10
@lymphomahub
Lymphoma Hub
5 months
CONGRESS | #18ICML | PRESENTATION Patrick B Johnston, @MayoClinic highlights results from the phase II DAILY II US trial of zamtocabtagene autoleucel in patients with R/R CNSL (N = 16). Zamto-cel was well tolerated in patients with R/R CNSL, with encouraging efficacy (ORR,
1
10
25
@FasaAgbedia
Owhofasa Agbedia, MD, MPH, FACP
5 months
Pola-R-CHP the new SOC for ALL DLBCL? @SoniSmithMD YES vs. @GregNowakowski NO Pola-R-CHP, RCHOP Some need Pola-R-CHP Some don't have access to Pola Some will be fine with RCHOP @icmlugano #18ICML #lymsm
5
3
9
@GregNowakowski
Greg
5 months
Dr Ansell discussing plenary abstract ICML Lugano on predicting response to CART by microenvironment signature @MayoCancerCare
3
4
34
@MayoCancerCare
Mayo Clinic Comprehensive Cancer Center
5 months
Late-breaking abstract featured at #ASCO25: @MayoClinic researchers found the addition of #immunotherapy to chemotherapy can reduce the recurrence and spread of #ColonCancer in patients with deficient DNA mismatch repair (dMMR). Learn more: https://t.co/0wfcqI8G2f @FASinicropeMD
1
10
23
@BloodCancerUtd
Blood Cancer United
11 months
Thank you @MayoClinic for recognizing Dr. Lee Greenberger, our SVP & Chief Scientific Officer of 11 years, for his service in the #BloodCancer space and collaboration in IMPACT grants last night. #ASH24 🔬🩸
0
6
16
@JasmineKambojMD
Jasmine Kamboj, MD, FASCO
1 year
Honored to be on the ballot for the Designated Community Oncology seat. ASCO has done a remarkable job of selecting a lineup of brilliant candidates. I personally have SO MUCH respect for each one of them! Your voice counts, please vote. https://t.co/TrPpQjHe2H @ASCO @ASCOPres
3
9
28
@YucaiWangMD
Yucai Wang, MD, PhD
1 year
We are seeking a lymphoma investigator to join our Lymphoid Malignancies Disease Group at @MayoClinic in Rochester, MN. Join @GregNowakowski, Steve Ansell, @WitzigLab and may other talented individuals to advance lymphoma care and research. https://t.co/tlKACrH7sR
1
7
30
@Lymphoma_Doc
Jason Westin, MD FACP FASCO
1 year
I’m honored to be on the ballot for the ASCO Board of Directors with all the other amazing candidates. Learn more and 🗳️ ⬇️
@ASCO
ASCO
1 year
Voting in the ASCO Election is open now until December 3! Meet the candidates for the Board of Directors – Undesignated Member seat. Learn more about each candidate, determine your voting eligibility, and make your voice heard at https://t.co/dvxay4gojm
1
10
46
@GregNowakowski
Greg
1 year
Great discussion on the present and future of oncology drug development with Dr. Rick Pazdur - Distinguished Lecturer at MCCCC. @realrickpazdur @MayoCancerCare @US_FDA
1
3
15
@MarekTrnenyDr
Marek Trneny
1 year
Dinner with ⁦@GregNowakowski⁩ and my excellent junior colleagues after great Gregg’ s talk and discussion in ⁦@UniKarlova⁩ Gen Hospital
2
2
13
@VincentRK
Vincent Rajkumar
1 year
100 years of Hematology @MayoClinic Rochester, MN Hematology Division Faculty @MayoCancerCare
6
19
160
@OncLive
OncLive.com
1 year
Grzegorz S. Nowakowski, MD, discusses the accelerated approval of epcoritamab in follicular lymphoma, touching on key trial data and remaining unmet needs. @GregNowakowski @MayoClinic #lymsm #oncology #MedTwitter
Tweet card summary image
onclive.com
Grzegorz S. Nowakowski, MD, discusses the accelerated approval of epcoritamab in follicular lymphoma, touching on key trial data and remaining unmet needs.
0
3
4
@MayoCancerCare
Mayo Clinic Comprehensive Cancer Center
1 year
Lots of great connections happening at #ASCO24 (mainly thanks to this pin). Stop by and say 👋 to Dr. @GregNowakowski and our experts at @MayoClinic booth no. 27104!
0
9
30
@c_thieblemont
C. Thieblemont
2 years
PhD thesis today @ComeBommier discussing about MZL, surrogacy, endpoints. Strong collaboration with Mayo Clinic, Congratulations !
5
4
40
@ASCO
ASCO
2 years
An ASCO task force paper published today in @JournalCancer details 3 calls-to-action for the oncology research and care communities that could expand access to clinical trials and enable patients to participate closer to home. Learn more: https://t.co/LRt7blr772 #OncTwitter
1
15
21
@Eddie_Cliff
Eddie Cliff
2 years
Great to join @FDAOncology, @AACR, @AmstatNews for today's workshop on Overall Survival in cancer clinical trials Nice introduction from @FDAOncology's Dr Gormley on different endpoint considerations & nuances of interpreting OS #AACRSciencePolicy @tmprowell
2
11
48
@DrAnasYounes
Anas Younes, M.D.
2 years
The Polish connection ⁦@GregNowakowski
0
2
11
@ASH_hematology
ASH
2 years
Join us for the ASH|FDA Collaboration: A Workshop on Regulatory Science in Hematology to gain a deeper understanding of the @US_FDA’s role in #hematology 🩸 Learn about product development, clinical trial design, & more! Apply now: https://t.co/tL38a4AfPs
0
2
11
@GregNowakowski
Greg
2 years
Looking forward joining discussion with great faculty colleagues at the PER symposium on experts addressing burning questions in DLBCL at ASCO in Chicago on June 2! Sign up today! https://t.co/kM5tda342t #HemOnc #gotoPER
1
1
10